#USA #New York #class action lawsuit #Faruqi & Faruqi #Jasper Therapeutics

Important Notice for Jasper Investors

On November 14, 2025, the renowned law firm Faruqi & Faruqi, LLP, announced significant information pertinent to investors of Jasper Therapeutics, Inc. (NASDAQ: JSPR). The firm is actively investigating potential claims against the company regarding a federal securities class action lawsuit, and they remind investors that there is an impending deadline of November 18, 2025, to seek the role of lead plaintiff in this case.

Understanding the Lawsuit

Investors who acquired shares in Jasper between November 30, 2023, and July 3, 2025, may have standing to join the class action lawsuit if they suffered losses. Faruqi & Faruqi’s partner James (Josh) Wilson has opened channels for those affected to reach out for further discussion about their rights and options relating to this lawsuit. Interested parties are encouraged to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

The company faces allegations of violating federal securities laws. It is alleged that Jasper and its executives made misleading statements or failed to inform investors about critical operational deficiencies. Specifically, it appears that Jasper lacked the necessary controls to ensure third-party manufacturers complied with current Good Manufacturing Practices (cGMP). This failure potentially jeopardizes the clinical trial processes and casts doubts over Jasper's product, briquilimab.

Consequences and Investor Impact

On July 7, 2025, Jasper revealed adverse information regarding its BEACON Study. The disclosure suggested significant issues with one drug product lot, which affected trial results and led to interruptions in the study. Furthermore, the company announced a halt to the development of briquilimab in the asthma market in addition to a broader restructuring plan aimed at cost reduction. These course corrections caused Jasper's stock price to plummet by 55.1%, closing at $3.04 per share—a stark indication of the damage these revelations caused to investor confidence.

Call to Action for Investors

The court will appoint a lead plaintiff, positioning them as a representative of the class members who share similar claims against Jasper Therapeutics. This role is crucial as the lead plaintiff will oversee the litigation process and direct the case's trajectory. However, members of the class also have the option to remain passive; they can choose not to apply to lead the lawsuit while still retaining the right to share in any recovery that may occur as a result of the litigation.

Those with insider knowledge regarding Jasper's operational capabilities or unethical practices are encouraged to reach out to the Faruqi & Faruqi firm. This includes whistleblowers, former employees, and anyone else who may have relevant information.

For further details on this situation regarding the class action case against Jasper Therapeutics, interested individuals can access more information at Faruqi & Faruqi's website or get in touch directly through the provided contact methods.

Conclusion

As the situation evolves, it is vital for Jasper investors to stay informed and take decisive action, especially in light of the looming November 18, 2025, deadline. Faruqi & Faruqi is dedicated to advocating for the interests of investors who may have been affected by Jasper's operational shortfalls. Keeping abreast of the developments in this critical lawsuit will ensure that investors are best positioned to protect their financial interests in light of current events.